ÂÜÀòÂÒÂ×

Fred Lynch is an experienced executive and board member with a robust background in leadership and operations across various industries. Currently serving as a board member at TileBar, Ascential Technologies, PST Process Sensing Technologies, Ingevity, and Moffitt Cancer Center, Lynch has also held the role of interim CEO at Verdesian Life Sciences. Previously, Lynch was the President and CEO of Masonite International and President of Human Generics at Actavis. Lynch's extensive tenure at Honeywell included several key positions, culminating as Vice President of Specialty Chemicals. Lynch holds an MBA in Finance from Temple University and a BS in Chemical Engineering from Villanova University.